ArticleProbiotics and antimicrobial proteins2025
Biogenic-Synthesized Silver Nanoparticles Using the Ligilactobacillus salivarius KC27L Postbiotic: Antimicrobial, Anti-Biofilm, and Antioxidant Activity and Cytotoxic Effects.
Article in Probiotics and antimicrobial proteins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Role of ProbioticsInternational journal of molecular sciences · 2026Review
- HarnessingInternational journal of nanomedicine · 2026Article
- Eco-friendly synthesis and biomedical potential of silver nanoparticles using Pandanus dubius extract.Scientific reports · 2025Article
- Green synthesis of silver iodide nanoparticles from Kluyveromyces marxianus M59 beta-glucan: characterization and anticancer activity.BMC biotechnology · 2025Article
- Nanoencapsulation of Biotics: Feasibility to Enhance Stability and Delivery for Improved Gut Health.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to synthesize silver nanoparticles (AgNPs) using the postbiotic of the Ligilactobacillus salivarius KC27L strain and evaluate their multifunctional biological properties. The use of L. salivarius, a probiotic bacterium known for its ability to produce a wide range of metabolites, plays a crucial role in this process by acting as a natural, eco-friendly reducing, and stabilizing agent during AgNP synthesis. This approach not only eliminates the need for hazardous chemicals typically used in nanoparticle synthesis but also enhances the biocompatibility and biological efficacy of the resulting nanoparticles. Synthesized AgNPs were analyzed by Fourier transform infrared spectroscopy, FTIR (metabolites of postbiotic); UV-vis (peak of 435 nm); scanning electron microscope, SEM; transmission electron microscopy, TEM (spherical shapes, sizes < 50 nm), energy-dispersive spectrometry, EDS (peak at 3 keV); and zeta potential (- 18.6 mV). These nanoparticles (0.156-40 mg/mL) were evaluated for the antimicrobial and anti-biofilm activities against Escherichia coli ATCC 11229, Pseudomonas aeruginosa ATCC 27853, Staphylococcus aureus ATCC 25923, Staphylococcus epidermidis ATCC 35984, and Streptococcus mutans ATCC 25175, and antioxidant activities using four different methods (2,2-diphenyl-1-picrylhydrazyl free radical scavenging, metal ion chelating, hydroxyl radical scavenging, and superoxide anion scavenging activities). Also, the cytotoxic activity was investigated against a normal cell line (L929) for 24, 48, and 72 h. At a concentration of 40 mg/mL, the AgNPs demonstrated the highest antimicrobial efficacy, with inhibition zones measured as 14.9 mm for P. aeruginosa, 9.5 mm for E. coli, 15.7 mm for S. epidermidis, and 12.9 mm for S. mutans. The AgNPs exhibited anti-biofilm activities against all Gram-positive and Gram-negative bacteria strains studied. According to the DPPH method, the highest antioxidant activity was determined at 40 mg/mL AgNP concentration (80.93%). AgNPs were found to have no toxic effect at low concentrations (0.39-25 µg/mL). Biogenic synthesized AgNPs could be used in biotechnological applications (biomaterials, health, environmental, etc.) with antibacterial, anti-biofilm, antioxidant, and nontoxic properties. However, further research is needed to understand the mechanisms of action of the particles fully.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.